BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ribaldone DG, Dileo I, Pellicano R, Resegotti A, Fagoonee S, Vernero M, Saracco G, Astegiano M. Severe ulcerative colitis: predictors of response and algorithm proposal for rescue therapy. Ir J Med Sci 2018;187:385-92. [PMID: 28756540 DOI: 10.1007/s11845-017-1666-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Dulai PS, Jairath V. Acute severe ulcerative colitis: latest evidence and therapeutic implications. Ther Adv Chronic Dis. 2018;9:65-72. [PMID: 29387331 DOI: 10.1177/2040622317742095] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
2 Lie MRKL, Paulides E, van der Woude CJ. Patient sex does not affect endoscopic outcomes of biologicals in inflammatory bowel disease but is associated with adverse events. Int J Colorectal Dis 2020;35:1489-500. [PMID: 32592091 DOI: 10.1007/s00384-020-03663-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Armandi A, Bonetto S, Pellicano R, Caviglia GP, Astegiano M, Saracco GM, Ribaldone DG. Dupilumab to target interleukin 4 for inflammatory bowel disease? Hypothesis based on a translational message. Minerva Biotecnol 2019;31. [DOI: 10.23736/s1120-4826.19.02556-4] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
4 Gisbert JP, Chaparro M. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. Journal of Crohn's and Colitis 2020;14:694-709. [DOI: 10.1093/ecco-jcc/jjz195] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 12.7] [Reference Citation Analysis]
5 Actis GC, Pellicano R, Fagoonee S, Ribaldone DG. History of Inflammatory Bowel Diseases. J Clin Med. 2019;8:1970. [PMID: 31739460 DOI: 10.3390/jcm8111970] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 10.3] [Reference Citation Analysis]
6 Choy MC, Seah D, Faleck DM, Shah SC, Chao CY, An YK, Radford-Smith G, Bessissow T, Dubinsky MC, Ford AC, Churilov L, Yeomans ND, De Cruz PP. Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis. Inflamm Bowel Dis 2019;25:1169-86. [PMID: 30605549 DOI: 10.1093/ibd/izy383] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 13.5] [Reference Citation Analysis]
7 Ribaldone DG, Pellicano R, Actis GC. The gut and the inflammatory bowel diseases inside-out: extra-intestinal manifestations. Minerva Gastroenterol Dietol 2019;65:309-18. [PMID: 30994321 DOI: 10.23736/S1121-421X.19.02577-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 4.7] [Reference Citation Analysis]
8 Lee SH, Walshe M, Oh EH, Hwang SW, Park SH, Yang DH, Byeon JS, Myung SJ, Yang SK, Greener T, Weizman AV, Silverberg MS, Ye BD. Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti-TNF Treatment. Inflamm Bowel Dis. 2020;. [PMID: 33269403 DOI: 10.1093/ibd/izaa309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]